当前位置：   首页 > 需求大厅

基因治疗的概念出现在几十年前,当研究人员推测,人类疾病可以通过精确使用一种技术引入外来DNA来解决遗传缺陷和疾病症状。近年来，基因治疗的进步已经涉足治疗遗传疾病，癌症，神经退行性疾病等各领域。遗传性疾病如色素性视网膜炎等少数眼部疾病的基因也可以如此治疗。公司征集一种在人类眼部组织定性和定量(半)测量体内基因表达的方法。 具体如下https://www.innocentive.com/ar/challenge/9933643 The concept of gene therapy arose decades ago, when researchers postulated that human diseases could be treated by using a technique to introduce foreign DNA to correct genetic defects and disease phenotypes. In recent years, advances in gene therapy have been documented in the treatment of genetic disorders, cancer, and neurodegenerative diseases. Inherited diseases such as retinitis pigmentosa are among a handful of ocular diseases that are amenable to gene therapy. The Seeker desires solutions that will both qualitatively and (semi-) quantitatively measure in vivo gene expression in human ocular tissues. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933643 Challenge Overview The number of clinical trials for gene therapy to treat ocular disorders is on the rise. Inherited diseases such as retinitis pigmentosa among others are thought to be good candidates for targeted treatment. Currently, there is no method in humans to determine the level or geographic location of transgene expression following administration of gene therapy for diseases of the eye, specifically the retina. The Seeker desires solutions that will both qualitatively and (semi-) quantitatively measure in vivo gene expression in human ocular tissues. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on June 20, 2015. Late submissions will not be considered. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, Solvers will grant to the Seeker a   [更多]

我们体内以分泌胰岛素来维持胰岛细胞血糖水平和体内平衡。而糖尿病患者的胰岛细胞是缺乏或无效的。没有足够活性的胰岛素，糖尿病患者就无法控制血糖。胰岛移植是一种治疗策略,糖尿病患者需要胰岛素注射来控制他们的疾病，减轻或根除症状。阿斯利康正在寻找一个简单的装置将人类胰岛移植出来，来检测药物的性能。 具体如下网站，https://www.innocentive.com/ar/challenge/9933735 Pancreatic islet beta-cells sense blood sugar levels and secrete insulin to maintain homeostasis. In patients with diabetes, islet beta-cells are either lacking or ineffective. Islet transplantation is a treatment strategy that allows diabetics to reduce or eliminate the need for insulin injections to control their disease. AstraZeneca is searching for a simple device to transplant human islets to facilitate testing of therapeutic agents. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933735 Challenge Overview Diabetes is a disease of the pancreatic islet cells. Of the four cell types, insulin-producing beta-cells are the most abundant. Without adequate levels of insulin, diabetes patients have difficulty controlling their blood sugar. One alternative to self-administration of medicine is islet transplantation. The procedure involves an infusion of isolated donor islets into the patient. If the graft is accepted, these islets will function to regulate blood glucose levels through the production of insulin. AstraZeneca is searching for a simple device for the transplantation and subsequent retrieval of human islets to support in vivo testing of therapeutic agents. ABOUT THE SEEKER AstraZeneca is a global, research-based, biopharmaceutical company with a focus on five key therapeutic areas: 1) cardiovascular & metabolic diseases, 2) oncology, 3) respiratory, inflammation & autoimmunity, 4) neuroscience, and 5) infection. As an innovation-driven, research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an avenue by which ideas can be shared and AstraZeneca recently launched a pavilion to further its commitment to facilitate the advancement of pharmaceutical   [更多]

具体要求：　要求工艺成熟,具有成本优势.   [更多]

具体要求：　最近的临床批件、正在进行临床研究的项目均可考虑   [更多]

【基本信息】 需要 受试者类型 ： 健康受试者 性 别 ： 女性 婚 姻 状 况 ： 不限 适 应 专 业 ： 药物适应症： 无 招 募 人 数： 600人 试验起止日期 ： 2015-04-07 -- 2015-06-30 报名截止日期 ： 2015-05-31 补 偿 金 ： ￥4000 【项目描述】 筛选过程：临床评估和问卷评估（约1.5小时） 评估合格拍照补贴车费60元，评估不合格做敏感测试，补贴车费20元 正式试验过程（约4小时）：洗脸→非创仪器检测（拍照+仪器检测）→问卷→医生采样①口水取样②皮肤贴片取样③用棉签取样④取表皮：面部靠近发际部位取2块2*2mm（约芝麻大小）皮肤，左手上臂内侧和前臂外侧各2块3*3mm（约米粒大小）皮肤，共计6块⑤血样采集。 之后的4次回访，进行换药和检查伤口约1小时。 【入选标准】 1. 20~49周岁居住上海健康女性，怀孕和哺乳期除外；2. 6个月未参加过面部产品测试项目；3.面部和左手臂无疤痕或纹身；4.无糖尿病史，无明显慢性皮肤病史；5.一个月内面部未局部使用药物；6.疤痕体质者除外。 【排除标准】 【研究中心列表】 上海 上海市皮肤病医院 【联系方式】 联系人 ： 杨医生 手 机 ： 18017336756   [更多]

现因发展需要，对外诚购中成药新药证书、临床批件。   [更多]

具体要求：现求购已获得的新药证书(包括改剂型新药证书)或临床批件，中西药均可。有意者可致电联系洽谈。   [更多]

具体要求：现批量购买保健食品批文，不限功能、批次。 有出让意向或近期获批的批文可与我公司联系。中介勿扰。   [更多]

BMS与Merck的PD-1抗体药物，2014年，由于治疗癌症效果异常显著，都获得了FDA突破性药物地位，目前免疫疗法已体现出成为继手术、放疗、化疗之后又一革命性抗癌技术，BMS的CTLA-4抗体已上市，与PD-1抗体连用可将癌症或者生存期提高3倍。目前本公司已构建PD-1抗体及CTLA-4抗体高表达细胞株，表达量在2g以上，发酵、纯化、质检工艺成熟，具备良好地商业开发价值和市场前景，美国市场预计BMS的nivolumab（PD-1抗体）年销售额保守可达60亿美元。   [更多]

我们需要设计自动崩解控制器用于靶向给药。自动崩解控制器，一旦触发，应该可以在温和条件(生理)下使药物分子的释放并激活。这个我们可以参考数量有限的文献中描述“self-immolative”（自动分解或自毁）连接器，但我们提出的自动崩解控制器不是这样的装置。具体链接为https://www.innocentive.com/ar/challenge/9933733，具体如下： Design of A Self-Cleaving Linker For Targeted Drug Delivery TAGS: Physical Sciences, Novel Molecules, Chemistry, Life Sciences, Theoretical-IP Transfer AWARD: $25,000 USD | DEADLINE: 4/27/15 | ACTIVE SOLVERS: 165 | POSTED: 3/26/15 The Seeker desires the design of a novel self-cleaving linker for use in targeted drug delivery. The self-cleaving linker, once triggered, should allow for the release of molecule(s) of interest under mild (physiological) conditions. A limited number of “self-immolative” linkers are well described in the literature and are specifically excluded from this Challenge. The Seeker specifically encourages synthetic chemists to consider this Challenge even if they do not have medicinal chemistry knowledge. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933733 Challenge Overview The Seeker desires the design of a novel self-cleaving linker for use in targeted drug delivery. The self-cleaving linker, once triggered, should allow for the release of molecule(s) of interest under mild (physiological) conditions. A limited number of such “self-immolative” linkers, based upon an elimination to generate a quinone methide, or utilizing a 5 or 6 member ring cyclization, are well described in the literature and are specifically excluded from this Challenge. The Seeker specifically encourages synthetic chemists to consider this Challenge even if they do not have medicinal chemistry knowledge. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, the Solvers will have to transfer to the Seeker their exclusive Intellectual Property   [更多]